Alteraciones metabólicas asociadas al uso de terapia antipsicótica

G, Paula Rojas; A, Catalina Poblete; G, Ximena Orellana; A, Karen Rouliez; G, Claudio Liberman

doi:10.4067/s0034-98872009000100017

Cited by 5 publications

(2 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The variation in patients' appetite does not help in predicting the APDs-induced body weight gain among the patients since some of the patients were reported to experience decreased appetite. It does however, shows that Olanzapine patients experienced higher increased appetite than the group that received Risperidone for their treatment 19 .…”

Section: Discussionmentioning

confidence: 86%

The Effects of Antipsychotic Drugs (Olanzapine and Risperidone) on Body Weight, Body Fat Percentage and Lipid Profiles of Patients with Psychotic Illness

George¹,

Yusuff²,

Shoesmith³

et al. 2019

BJMS

View full text Add to dashboard Cite

Approximately 50% patients with psychotic illnesses on antipsychotic drugs have an increased risk of obesity. This study aimed to determine changes in body weight, body fat percentage and lipid profiles and to stress the importance of early nutrition intervention in the management of psychotic illness patient treated with antipsychotic drugs. This is a prospective longitudinal study conducted for 3 months in Hospital Mesra Bukit Padang, Kota Kinabalu, Sabah. A total of 150 patients with Diagnostic and Statistical Manual IV (DSM-IV) diagnosis of psychotic illness (either Olanzapine or Risperidone only at any dosage) first started or restarted after a treatment gap of at least 6 months were recruited. Weight, height and body fat percentage were measured using Bioelectrical Impedance Analysis (BIA) (Model Omron HBF-375) and blood fasting lipid test were taken from the point of starting medication for 12 weeks. Data were analysed using repeated measures of ANOVA for statistical method. All variables showed significant mean differences (p < 0.05) in increasing pattern throughout the 12 weeks of treatment. However, the total cholesterol of risperidone patients had no significant mean difference from initial to week 6 (p = 0.282). It was proven that there was increase in body weight, body fat percentage and lipid profiles among patients on olanzapine and risperidone. The limitation of this study might relate to the drugsâ€™ dosage and method used in assessing the body composition. It is suggested that early nutrition intervention is needed to control unnecessary gain of weight, body fat and lipid profiles in the management of patient with psychotic illnesses.

show abstract

Section: Discussionmentioning

confidence: 86%

The Effects of Antipsychotic Drugs (Olanzapine and Risperidone) on Body Weight, Body Fat Percentage and Lipid Profiles of Patients with Psychotic Illness

George¹,

Yusuff²,

Shoesmith³

et al. 2019

BJMS

View full text Add to dashboard Cite

show abstract

“…Por otra parte, al agrupar los pacientes por tipo de tratamiento, las personas que estaban con antipsicóticos atípicos presentaron mayor IMC, CC y porcentaje de grasa corporal, en comparación a las otras terapias. Se ha señalado incremento del depósito de grasa subcutánea y abdominal, así como aumento de peso con el uso de estos medicamentos 29 . Se encontraron diferencias significativas en la CC en pacientes que estaban con antipsicóticos atípicos y estabilizador de ánimo.…”

Section: Discussionunclassified